Cost-effectiveness of Dapagliflozin in the treatment of chronic symptomatic hearth failure with reduced ejection fraction in the Netherlands

Ingelin Kvamme, Gimon de Graaf, Susanne Nekemann, Stijn Gijsbers, Valerie Wester, Martine Hoogendoorn

Research output: Contribution to journalMeeting AbstractAcademic

Fingerprint

Dive into the research topics of 'Cost-effectiveness of Dapagliflozin in the treatment of chronic symptomatic hearth failure with reduced ejection fraction in the Netherlands'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science